|
Name |
Company |
Description |
|
Phase III | ||
|
Denosumab (AMG 162) |
Amgen |
Human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone destruction; trials testing denosumab alone and in combination with Zometa completed; under review by the FDA |
|
Panobinostat (LBH589) |
Novartis |
Deacetylase (DAC) inhibitor; being evaluated in combination with other agents LEARN MORE |
|
Perifosine (KRX-0401, D-21266) |
Keryx |
Oral anticancer agent that inhibits cell growth and promotes apoptosis; being evaluated alone and combination with other agents LEARN MORE |
|
Zolinza® (vorinostat, SAHA [suberoylanilide hydroxamic acid]) |
Merck |
Histone deacetylase (HDAC) inhibitor that has shown activity in relapsed and refractory myeloma LEARN MORE |
|
Phase II | ||
|
Afinitor® (everolimus, RAD001, Certican®) |
Novartis |
mTor inhibitor being evaluated in combination with other agents; known as Certican outside the US, where it is used in preventing transplant rejection |
|
Aflibercept (VEGF Trap) |
Regeneron/sanofi-aventis |
Anti-angiogenic fusion protein that binds VEGF |
|
Aplidin® (plitidepsin) |
PharmaMar, SA |
Marine-derived antitumor agent that induces rapid apoptosis LEARN MORE |
|
Avastin® |
Genentech |
Humanized antibody against the VEGF receptor FDA-approved for use in other cancers; being evaluated as part of several combination therapies |
|
Bexxar® (iodine I 131 tositumomab) |
GlaxoSmithKline |
FDA-approved radiolabeled monoclonal antibody directed against CD20, a marker found on B cells and 20% to 25% of myeloma cells |
|
Carfilzomib (PR-171) |
Oxyx Pharmaceuticals |
Proteasome inhibitor being evaluated alone, as part of combination therapy, and as maintenance therapy LEARN MORE |
|
CNTO 328 |
Centocor Ortho Biotec |
Anti-interleukin-6 monoclonal antibody being evaluated alone and in combination with Velcade and Velcade-MP LEARN MORE |
|
Elotuzumab (HuLuc63; humanized anti-CS1 monoclonal antibody) |
Facet Biotech/Bristol-Myers Squibb |
Monoclonal antibody that binds to CS1, a cell surface protein that is highly expressed on myeloma cells; being evaluated alone and in combination with Velcade and with Revlimid-Dex LEARN MORE |
|
IPH2101 |
Innate Pharma |
Monoclonal antibody that enhances killing of myeloma cells by natural killer (NK) cells |
|
Istodax® (romidepsin) |
Celgene |
Histone deacetylase (HDAC) inhibitor approved for use in a specific type of lymphoma; being evaluated in combination with Velcade |
|
Nexavar® (sorafenib) |
Bayer/Onyx Pharmaceuticals |
Multi-kinase inhibitor FDA-approved for use in renal cell carcinoma that inhibits cell growth and angiogenesis; being evaluated alone and in combination with other agents |
|
PD 0332991 |
Pfizer |
Kinase inhibitor being evaluated in combination with Velcade and dexamethasone |
|
Pomalidomide (CC-4047) |
Celgene Corporation |
Type of IMiD™ (immunomodulatory drug) being evaluated alone and in combination with dexamethasone LEARN MORE |
|
Rituxan® (rituximab) |
Genentech/Biogen Idec |
Monoclonal antibody FDA-approved for use in non-Hodgkin lymphoma that targets the CD20 marker found on B cells and 20% to 35% of myeloma cells |
|
SRT501 |
Sirtris, a GlaxoSmithKline company |
A formulation of resveratrol (compound found in grapes and red wine) being evaluated alone and in combination with Velcade |
|
TKI258 |
Novartis |
Oral tyrosine kinase inhibitor that displays antitumor activity and inhibits angiogenesis |
|
Romidepsin (depsipeptide, FK228, FR901228) |
Gloucester Pharmaceuticals/Janssen-Cilag Ltd. |
Histone deacetylase (HDAC) inhibitor being evaluated in combination with Velcade |
|
Sprycel® (dasatinib) |
Bristol-Myers Squibb |
Kinase inhibitor FDA-approved for use in chronic myelogenous leukemia; being evaluated in combination with Velcade or Revlimid-dex |
|
Torisel™ (temsirolimus, CCI-779) |
Wyeth |
mTOR inhibitor FDA-approved for use in renal cell carcinoma; being evaluated alone and in combination with other agents |
|
Trisenox® (arsenic |
Cephalon |
Anticancer drug FDA-approved for use in acute promyelocytic leukemia |
|
Vidaza® (azacitidine) |
Celgene |
Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS) |
|
Zarnestra™ (R115777, tipifarnib,FTI) |
Ortho Biotech Oncology Research & Development |
Farnesyl transferase inhibitor; activity seen in combination with Velcade in a phase I trial |
|
Phase I | ||
|
Anti-KIR (1-7F9) |
Novo Nordisk |
Monoclonal antibody that activates the body's natural killer cells to kill tumor cells |
|
ARRY-520 |
Array BioPharma |
Agent shown to be effective alone and in combination with Velcade or Revlimid in a mouse model of myeloma |
|
AUY922 |
Novartis |
Heat shock protein (HSP90) inhibitor being tested alone and in combination with other Velcade, with or without dexamethasone |
|
BI-505 |
BioInvent International AB |
Monoclonal antibody directed against ICAM-1, a protein that enables immune cells to migrate from the blood into tissues |
|
BKT140 |
Biokine Therapeutics |
Novel agent that causes myeloma cell death |
|
BMS-833923 |
Bristol-Myers Squibb |
Oral anticancer agent being evaluated alone and in combination with Revlimid-dex or Velcade |
|
BT062 |
Biotest AG |
Anti-CD138 monoclonal antibody/cytotoxic agent compound that has demonstrated activity in early testing |
|
CEP-18770 |
Cephalon |
Proteasome inhibitor |
|
Dacetuzumab (SGN40) |
Seattle Genetics |
Monoclonal antibody directed against CD40 that has shown activity in combination with Revlimid-dex; also being evaluated in combination with Velcade |
|
GRN163L |
Geron Corp. |
Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth; being evaluated alone and in combination with Velcade |
|
HCD122 |
Novartis |
Anti-CD40 monoclonal antibody |
|
HuMax-CD38 |
Genmab |
Human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of myeloma cells |
|
Imetelstat (GRN163L) |
Geron Corp. |
Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth; being evaluated alone and in combination with Velcade |
|
IMGN901 (huN901-DM1, BB-10901) |
Immunogen |
Monoclonal antibody directed against the CD56 marker found on myeloma cells, coupled with a cancer drug; activity shown in heavily pretreated myeloma |
|
LY2127399 |
Lilly |
Antibody directed against a protein that activates B cells being tested in combination with Velcade |
|
Milatuzumab (hLL1, IMMU-110) |
Immunomedics |
Humanized monoclonal antibody directed against the CD74 protein found on B cells and myeloma cells |
|
MLN4924 |
Millennium: The Takeda Oncology Company |
Novel agent |
|
MLN8237 |
Millennium: The Takeda Oncology Company |
Novel agent (Aurora A kinase inhibitor) being evaluated in combination with Velcade |
|
MLN9708 |
Millennium: The Takeda Oncology Company |
Oral second-generation proteasome inhibitor |
|
Noscapine (CB3304) |
Johnson & Johnson |
Cough suppressant that inhibits the growth of several types of cancer cells |
|
NPI-0052 |
Nereus |
Novel proteasome inhibitor that has shown promising early safety data |
|
Oncolytic measles virus (MV-NIS) |
Mayo Clinic |
Genetically engineered measles virus being administered with or without cyclophosphamide |
|
Salinosporamide A (NPI-0052) |
Nereus Pharmaceuticals |
Novel marine derived proteasome inhibitor active against myeloma cells that are resistant to Velcade |
|
SGN40 |
Seattle |
Monoclonal antibody directed against CD40 being evaluated in combination with Revlimid-dex or Velcade |
|
Treanda®, |
Cephalon Oncology |
Alkylating agent FDA-approved for use in treating leukemia and approved in Germany for use in myeloma; being evaluated as part of various combination therapies for use in newly diagnosed and relapsed and/or refractory disease |
|
Zemplar™ (paricalcitol) |
Abbott |
Activated vitamin D therapy being evaluated in combination with Zometa |
|
Zevalin® (yttrium Y 90 ibritumomab tiuxetan) |
Cell Therapeutics, Inc. |
Radiolabeled monoclonal antibody FDA-approved for use in combination with Rituxan (rituximab) for the B-cell non-Hodgkin’s lymphoma; the combination is being evaluated prior to high-dose melphalan and stem cell transplant |
 |
|
|
Corporate Supporters | Terms of Use | Privacy Policy Copyright © 2010 Multiple Myeloma Research Foundation |
